LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Начало・Списък с акции・MacroGenics Inc

MacroGenics Inc

Затворен

СекторЗдравеопазване

4.52 6.1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.41

Максимум

4.52

Ключови измерители
By Trading Economics
Приходи	-23M -37M
Продажби	-20M 21M
EPS	-0.58
Марж на печалбата	-177.011
Служители	293
EBITDA	-17M -32M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+39.74% upside

Дивиденти
By Dow Jones
Следващи печалби	12.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	89M 276M
Предишно отваряне	-1.58
Предишно затваряне	4.52

Настроения в новините

By Acuity

50%

159 / 345 Класиране в Healthcare

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.05.2026 г., 08:24 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25.05.2026 г., 21:22 ч. UTC

Печалби

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Basic Materials Roundup: Market Talk

25.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Basic Materials Roundup: Market Talk

25.05.2026 г., 16:01 ч. UTC

Пазарно говорене

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25.05.2026 г., 14:43 ч. UTC

Пазарно говорене

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25.05.2026 г., 14:15 ч. UTC

Пазарно говорене

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25.05.2026 г., 13:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

25.05.2026 г., 12:58 ч. UTC

Пазарно говорене

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25.05.2026 г., 12:56 ч. UTC

Пазарно говорене

Печалби

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25.05.2026 г., 12:48 ч. UTC

Пазарно говорене

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25.05.2026 г., 12:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

25.05.2026 г., 12:34 ч. UTC

Пазарно говорене

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25.05.2026 г., 12:10 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Delivery Hero's Assets Look Strategic -- Market Talk

25.05.2026 г., 11:00 ч. UTC

Пазарно говорене

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25.05.2026 г., 10:19 ч. UTC

Пазарно говорене

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25.05.2026 г., 10:05 ч. UTC

Печалби

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25.05.2026 г., 10:04 ч. UTC

Печалби

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25.05.2026 г., 10:03 ч. UTC

Печалби

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25.05.2026 г., 10:02 ч. UTC

Печалби

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25.05.2026 г., 10:01 ч. UTC

Печалби

Tenaga Nasional 1Q Net Up 3.7% on Year

25.05.2026 г., 10:00 ч. UTC

Печалби

Tenaga Nasional 1Q Rev Up 6.6% on Year

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional 1Q EPS MYR0.1883

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional 1Q Rev MYR17.1B

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional 1Q Net MYR1.1B

25.05.2026 г., 09:38 ч. UTC

Пазарно говорене

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25.05.2026 г., 09:33 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

25.05.2026 г., 09:33 ч. UTC

Пазарно говорене

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25.05.2026 г., 08:55 ч. UTC

Пазарно говорене

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

39.74% нагоре

12-месечна прогноза

Среден 6.33 USD 39.74%

Висок 9 USD

Нисък 4 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на MacroGenics Inc през последните 3 месеца.

Настроение

By Acuity

159 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.